Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's disease.
CEACAM6. IBD
Crohn's disease
adherent-invasive E. coli
anti-E. coli antibodies
inflammatory bowel disease
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
25
03
2021
accepted:
27
07
2021
entrez:
18
11
2021
pubmed:
19
11
2021
medline:
22
2
2022
Statut:
ppublish
Résumé
The identification of Crohn's disease (CD)-associated adherent and invasive Escherichia coli (AIEC) is time-consuming and requires ileal biopsies. We aimed to identify a faster and less invasive methods to detect ileal colonization by AIEC in CD patients. CD patients requiring ileo-colonoscopy were consecutively enrolled in this prospective multicenter study. Samples from saliva, serum, stools, and ileal biopsies of CD patients were collected. Among 102 CD patients, the prevalence of AIEC on ileal biopsies was 24.5%. The abundance and global invasive ability of ileal-associated total E. coli were respectively ten-fold (p = 0.0065) and two-fold (p = 0.0007) higher in AIEC-positive (vs. AIEC-negative), while abundance of total E. coli in the feces was not correlated with AIEC status in the ileum. The best threshold of ileal total E. coli was 60 cfu/biopsy to detect AIEC-positive patients, with high negative predictive value (NPV) (94.1%[80.3-99.3]), while the global invasive ability (>9000 internalized bacteria) was able to detect the presence of AIEC with high positive predictive value (80.0% [55.2-100.0]). Overall, 78.1% of the AIEC + patients were colonized by two or less different AIEC strains. The level of serum anti-total E. coli antibodies (AEcAb) was higher in AIEC-positive patients (p = 0.038) with a very high negative predictive value (96.6% [89.9-100.0]) (p = 0.038) for a cut-off value > 1.9 × 10 More than two thirds of AIEC-positive CD patients were colonized by two or less AIEC strains. While stools samples are not accurate to screen AIEC status, the AEcAb level appears to be an attractive, rapid and easier biomarker to identify patients with Crohn's disease harboring AIEC.
Sections du résumé
BACKGROUND AND AIMS
The identification of Crohn's disease (CD)-associated adherent and invasive Escherichia coli (AIEC) is time-consuming and requires ileal biopsies. We aimed to identify a faster and less invasive methods to detect ileal colonization by AIEC in CD patients.
METHODS
CD patients requiring ileo-colonoscopy were consecutively enrolled in this prospective multicenter study. Samples from saliva, serum, stools, and ileal biopsies of CD patients were collected.
RESULTS
Among 102 CD patients, the prevalence of AIEC on ileal biopsies was 24.5%. The abundance and global invasive ability of ileal-associated total E. coli were respectively ten-fold (p = 0.0065) and two-fold (p = 0.0007) higher in AIEC-positive (vs. AIEC-negative), while abundance of total E. coli in the feces was not correlated with AIEC status in the ileum. The best threshold of ileal total E. coli was 60 cfu/biopsy to detect AIEC-positive patients, with high negative predictive value (NPV) (94.1%[80.3-99.3]), while the global invasive ability (>9000 internalized bacteria) was able to detect the presence of AIEC with high positive predictive value (80.0% [55.2-100.0]). Overall, 78.1% of the AIEC + patients were colonized by two or less different AIEC strains. The level of serum anti-total E. coli antibodies (AEcAb) was higher in AIEC-positive patients (p = 0.038) with a very high negative predictive value (96.6% [89.9-100.0]) (p = 0.038) for a cut-off value > 1.9 × 10
CONCLUSIONS
More than two thirds of AIEC-positive CD patients were colonized by two or less AIEC strains. While stools samples are not accurate to screen AIEC status, the AEcAb level appears to be an attractive, rapid and easier biomarker to identify patients with Crohn's disease harboring AIEC.
Identifiants
pubmed: 34791806
doi: 10.1002/ueg2.12161
pmc: PMC8598958
doi:
Substances chimiques
Antibodies, Bacterial
0
Biomarkers
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1007-1018Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Lab Invest. 2012 Mar;92(3):411-9
pubmed: 22042084
Gut Microbes. 2012 Nov-Dec;3(6):544-55
pubmed: 23060017
World J Gastroenterol. 2016 Jan 21;22(3):1304-10
pubmed: 26811667
mBio. 2015 Nov 17;6(6):e01298-15
pubmed: 26578673
PLoS One. 2019 Sep 12;14(9):e0222168
pubmed: 31513633
Curr Microbiol. 2011 Aug;63(2):131-7
pubmed: 21626145
J Gastroenterol Hepatol. 2021 Apr;36(4):852-863
pubmed: 32929762
Gut. 2017 Aug;66(8):1382-1389
pubmed: 27196580
Gut. 1989 Jul;30(7):983-9
pubmed: 2668130
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Gut. 2012 Feb;61(2):241-7
pubmed: 21646246
Biomed Res Int. 2014;2014:567929
pubmed: 25580435
World J Gastroenterol. 2014 Feb 7;20(5):1192-210
pubmed: 24574795
Gastroenterology. 2015 Jan;148(1):52-63.e3
pubmed: 25241327
Nat Commun. 2013;4:1957
pubmed: 23748852
J Clin Invest. 2007 Jun;117(6):1566-74
pubmed: 17525800
Chembiochem. 2016 May 17;17(10):936-52
pubmed: 26946458
Gastroenterology. 1998 Dec;115(6):1405-13
pubmed: 9834268
Inflamm Bowel Dis. 2017 Aug;23(8):1425-1433
pubmed: 28570431
Int J Food Microbiol. 2009 Jun 30;132(2-3):172-5
pubmed: 19427046
World J Biol Chem. 2020 Apr 7;11(1):1-13
pubmed: 32405343
Gut. 2018 Mar;67(3):574-587
pubmed: 29141957
PLoS Pathog. 2013 Jan;9(1):e1003141
pubmed: 23358328
Sci Transl Med. 2017 Feb 8;9(376):
pubmed: 28179509
Inflamm Bowel Dis. 2015 Feb;21(2):276-86
pubmed: 25569734
J Crohns Colitis. 2021 Jun 22;15(6):1000-1008
pubmed: 33313808
Gastroenterology. 2004 Aug;127(2):412-21
pubmed: 15300573
Inflamm Bowel Dis. 2009 Jun;15(6):872-82
pubmed: 19235912